These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 8722370)

  • 1. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation.
    Yu C; Storb R; Deeg HJ; Graham TC; Scheuning FG; Huss R; Seidel K; Fitzsimmons WE
    Bone Marrow Transplant; 1996 Apr; 17(4):649-53. PubMed ID: 8722370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoids fail to enhance the effect of FK506 and methotrexate in prevention of graft-versus-host disease after DLA-nonidentical, unrelated marrow transplantation.
    Yu C; Seidel K; Fitzsimmons WE; Sale G; Storb R
    Bone Marrow Transplant; 1997 Jul; 20(2):137-41. PubMed ID: 9244417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of graft-versus-host disease by immunosuppressive agents after transplantation of DLA-nonidentical canine marrow.
    Storb R; Kolb HJ; Deeg HJ; Weiden PL; Appelbaum F; Graham TC; Thomas ED
    Bone Marrow Transplant; 1986 Dec; 1(2):167-77. PubMed ID: 3332131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors.
    Storb R; Raff RF; Appelbaum FR; Deeg HJ; Fitzsimmons W; Graham TC; Pepe M; Pettinger M; Sale G; van der Jagt R
    Transplantation; 1993 Oct; 56(4):800-7. PubMed ID: 7692635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
    Hamazaki T; Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Sasabe M; Kishimoto T; Inoue A; Kawa K
    Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Resistance' to unrelated, DLA-nonidentical canine marrow grafts is unrestricted by the major histocompatibility complex.
    Raff RF; Sandmaier BM; Graham T; Loughran TP; Pettinger M; Storb R
    Exp Hematol; 1994 Aug; 22(9):893-7. PubMed ID: 8062888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies.
    Uberti JP; Silver SM; Adams PT; Jacobson P; Scalzo A; Ratanatharathorn V
    Bone Marrow Transplant; 1997 Jun; 19(12):1233-8. PubMed ID: 9208118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation.
    Yanik G; Levine JE; Ratanatharathorn V; Dunn R; Ferrara J; Hutchinson RJ
    Bone Marrow Transplant; 2000 Jul; 26(2):161-7. PubMed ID: 10918426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients.
    Wingard JR; Nash RA; Ratanatharathorn V; Fay JW; Klein JL; Przepiorka D; Maher RM; Devine SM; Boswell G; Bekersky I; Fitzsimmons W
    Bone Marrow Transplant; 1997 Jul; 20(1):49-51. PubMed ID: 9232256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of trimetrexate for the prevention of graft-versus-host disease.
    Appelbaum FR; Raff RF; Storb R; Deeg HJ; Graham TC; Sandmaier B; Schuening F
    Bone Marrow Transplant; 1989 Jul; 4(4):421-4. PubMed ID: 2528387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.
    Przepiorka D; Khouri I; Ippoliti C; Ueno NT; Mehra R; Körbling M; Giralt S; Gajewski J; Fischer H; Donato M; Cleary K; Claxton D; Chan KW; Braunschweig I; van Besien K; Andersson BS; Anderlini P; Champlin R
    Bone Marrow Transplant; 1999 Oct; 24(7):763-8. PubMed ID: 10516680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
    Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfusion of autologous cytotoxic cells leads to failure of unrelated, DLA-nonidentical marrow grafts.
    Loughran TP; Raff RF; Graham TC; Appelbaum FR; Schuening FG; Sale GE; Storb R
    Exp Hematol; 1990 Nov; 18(10):1126-31. PubMed ID: 2209768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [FK506 for the prophylaxis of graft-versus-host-disease after bone marrow transplantation from HLA-genotypically mismatched unrelated donor].
    Nishida T; Haneda M; Kanie T; Murata M; Hamaguchi M; Minami S; Kodera Y
    Rinsho Ketsueki; 1998 Aug; 39(8):574-9. PubMed ID: 9785975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies.
    Mori T; Aisa Y; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Yamane A; Ikeda Y; Okamoto S
    Transplant Proc; 2007 Jun; 39(5):1615-9. PubMed ID: 17580201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Limb allograft in rats: studies on optimal maintenance dose of FK506 and development of graft-versus-host-disease (GVHD)].
    Weigao C
    Fukuoka Igaku Zasshi; 1996 Sep; 87(9):197-205. PubMed ID: 8913057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation.
    Koehler MT; Howrie D; Mirro J; Neudorf S; Blatt J; Corey S; Wollman M; Kelly-Ekeroth V; Reyes J
    Bone Marrow Transplant; 1995 Jun; 15(6):895-9. PubMed ID: 7581088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group.
    Kanamaru A; Takemoto Y; Kakishita E; Dohy H; Kodera Y; Moriyama Y; Shibata A; Kasai M; Katoh S; Saitoh H
    Bone Marrow Transplant; 1995 Jun; 15(6):885-9. PubMed ID: 7581086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.